Skip to main content
. 2015 Dec 30;10(12):e0145380. doi: 10.1371/journal.pone.0145380

Fig 2. Proportion (95% CI) receiving RHZ-based empiric therapy (a) and proportion (95%CI) with MDR-TB (b) in different countries and study regions.

Fig 2

The intraregional differences in the use of RHZ-based empiric anti-TB treatment are shown in relation to the observed MDR-TB prevalence.